Volume | 9,912,278 |
|
|||||
News | - | ||||||
Day High | 0.199089 | Low High |
|||||
Day Low | 0.1524 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Kintara Therapeutics Inc | KTRA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.1885 | 0.1524 | 0.199089 | 0.157 | 0.184 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,849 | 9,912,278 | $ 0.1754577 | $ 1,739,185 | - | 0.081 - 5.60 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:04:21 | formt | 189 | $ 0.1686 | USD |
Kintara Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.25M | 39.04M | - | 0 | -15.02M | -0.38 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Kintara Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KTRA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.1281 | 0.199089 | 0.1276 | 0.1661565 | 20,941,429 | 0.0405 | 31.62% |
1 Month | 0.1361 | 0.199089 | 0.125 | 0.1578395 | 10,729,145 | 0.0325 | 23.88% |
3 Months | 0.1099 | 0.24 | 0.081 | 0.1401243 | 13,694,849 | 0.0587 | 53.41% |
6 Months | 0.37 | 0.4961 | 0.081 | 0.1408388 | 11,363,682 | -0.2014 | -54.43% |
1 Year | 3.04 | 5.60 | 0.081 | 0.1768871 | 5,761,619 | -2.87 | -94.45% |
3 Years | 77.00 | 142.50 | 0.081 | 9.37 | 2,968,830 | -76.83 | -99.78% |
5 Years | 60.50 | 167.50 | 0.081 | 13.64 | 2,487,777 | -60.33 | -99.72% |
Kintara Therapeutics Description
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. |